Literature DB >> 18350631

Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: a randomized controlled trial.

Binay-K De1, Deep Dutta, Rimi Som, Pranab-K Biswas, Subrata-K Pal, Anirban Biswas.   

Abstract

AIM: To study the hemodynamic effects of spironolactone with propranolol vs propranolol alone in the secondary prophylaxis of variceal bleeding.
METHODS: Thirty-five cirrhotics with variceal bleeding randomly received propranolol (n = 17: Group A) or spironolactone plus propranolol (n = 18: Group B). Hemodynamic assessment was performed at baseline and on the eighth day.
RESULTS: Spironolactone with propranolol caused a greater reduction in the hepatic venous pressure gradient than propranolol alone (26.94% vs 10.2%; P < 0.01). Fourteen out of eighteen patients on the combination treatment had a reduction in hepatic venous pressure gradient to <= 12 mmHg or a 20% reduction from baseline in contrast to only six out of seventeen (6/17) on propranolol alone (P < 0.05).
CONCLUSION: Spironolactone with propranolol results in a better response with a greater reduction in hepatic venous pressure gradient in the secondary prophylaxis of variceal bleeding. A greater number of patients may be protected by this combination therapy than by propranolol alone. Hence, this combination may be recommended for secondary prophylaxis in patients with variceal bleeding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18350631      PMCID: PMC2700421          DOI: 10.3748/wjg.14.1908

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  29 in total

Review 1.  Influence of pharmacological agents on portal hemodynamics: basis for its use in the treatment of portal hypertension.

Authors:  J C García-Pagán; A Escorsell; E Moitinho; J Bosch
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

2.  Endoscopic ligation compared with combined treatment with nadolol and isosorbide mononitrate to prevent recurrent variceal bleeding.

Authors:  C Villanueva; J Miñana; J Ortiz; A Gallego; G Soriano; X Torras; S Sáinz; J Boadas; X Cussó; C Guarner; J Balanzó
Journal:  N Engl J Med       Date:  2001-08-30       Impact factor: 91.245

3.  Dose-dependent endothelial cell growth and stiffening by aldosterone: endothelial protection by eplerenone.

Authors:  Uta Hillebrand; Hermann Schillers; Christoph Riethmüller; Christian Stock; Marianne Wilhelmi; Hans Oberleithner; Martin Hausberg
Journal:  J Hypertens       Date:  2007-03       Impact factor: 4.844

4.  Wedged and free hepatic venous pressure measured with a balloon catheter.

Authors:  R J Groszmann; M Glickman; A T Blei; E Storer; H O Conn
Journal:  Gastroenterology       Date:  1979-02       Impact factor: 22.682

5.  Hemodynamic effect of spironolactone in liver cirrhosis and propranolol-resistant portal hypertension.

Authors:  Sambit Sen; Binay K De; Pranab K Biswas; Jayanta Biswas; Debasish Das; Ajit K Maity
Journal:  Indian J Gastroenterol       Date:  2002 Jul-Aug

6.  Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.

Authors:  Juan G Abraldes; Ilaria Tarantino; Juan Turnes; Juan Carlos Garcia-Pagan; Juan Rodés; Jaime Bosch
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

7.  "A La Carte" treatment of portal hypertension: Adapting medical therapy to hemodynamic response for the prevention of bleeding.

Authors:  Christophe Bureau; Jean-Marie Péron; Laurent Alric; Joséphine Morales; Jérôme Sanchez; Karl Barange; Jean-Louis Payen; Jean-Pierre Vinel
Journal:  Hepatology       Date:  2002-12       Impact factor: 17.425

8.  Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis.

Authors:  Càndid Villanueva; Josep M López-Balaguer; Carles Aracil; Lilian Kolle; Begoña González; Josep Miñana; German Soriano; Carlos Guarner; Joaquim Balanzó
Journal:  J Hepatol       Date:  2004-05       Impact factor: 25.083

9.  Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study.

Authors:  Raquel Abecasis; David Kravetz; Eduardo Fassio; Beatriz Ameigeiras; Daniel Garcia; Rogelio Isla; Graciela Landeira; Nora Dominguez; Gustavo Romero; Julio Argonz; Ruben Terg
Journal:  Hepatology       Date:  2003-02       Impact factor: 17.425

10.  A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis.

Authors:  D Patch; C A Sabin; J Goulis; G Gerunda; L Greenslade; C Merkel; A K Burroughs
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

View more
  3 in total

1.  Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis.

Authors:  Jianrong Wang; Wenxia Lu; Jingjing Li; Rong Zhang; Yuqing Zhou; Qin Yin; Yuanyuan Zheng; Fan Wang; Yujing Xia; Kan Chen; Sainan Li; Tong Liu; Jie Lu; Yingqun Zhou; Chuan-Yong Guo
Journal:  Exp Ther Med       Date:  2017-03-09       Impact factor: 2.447

2.  Treatment for bleeding oesophageal varices in people with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Danielle Roberts; Lawrence Mj Best; Suzanne C Freeman; Alex J Sutton; Nicola J Cooper; Sivapatham Arunan; Tanjia Begum; Norman R Williams; Dana Walshaw; Elisabeth Jane Milne; Maxine Tapp; Mario Csenar; Chavdar S Pavlov; Brian R Davidson; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2021-04-10

3.  Efficacy and Safety of Novel Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in the Management of Diabetic Kidney Disease: A Meta-analysis.

Authors:  Deep Dutta; Vineet Surana; Saptarshi Bhattacharya; Sameer Aggarwal; Meha Sharma
Journal:  Indian J Endocrinol Metab       Date:  2022-04-29
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.